Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Marks

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Bioorganic & Medicinal Chemistry|June 5, 2007
Pyrrolidinones as orally bioavailable antagonists of the human melanocortin-4 receptor with anti-cachectic activityJoe A Tran, Fabio C Tucci, Wanlong Jiang, et al.
Bioorganic & Medicinal Chemistry|April 18, 2008
Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonistsChen Chen, Fabio C Tucci, Wanlong Jiang, et al.
Journal of Medicinal Chemistry|November 13, 2007
Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptorJoe A Tran, Wanlong Jiang, Fabio C Tucci, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 23, 2008
Cachexia: a new definitionWilliam J Evans, John E Morley, Josep Argilés, et al.
Nature Communications|March 18, 2026
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitorsCarmen R Moncayo, Restuadi Restuadi, Guanying Zhang, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Bioorganic & Medicinal Chemistry|June 5, 2007
Pyrrolidinones as orally bioavailable antagonists of the human melanocortin-4 receptor with anti-cachectic activityJoe A Tran, Fabio C Tucci, Wanlong Jiang, et al.
Bioorganic & Medicinal Chemistry|April 18, 2008
Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonistsChen Chen, Fabio C Tucci, Wanlong Jiang, et al.
Journal of Medicinal Chemistry|November 13, 2007
Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptorJoe A Tran, Wanlong Jiang, Fabio C Tucci, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 23, 2008
Cachexia: a new definitionWilliam J Evans, John E Morley, Josep Argilés, et al.
Nature Communications|March 18, 2026
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitorsCarmen R Moncayo, Restuadi Restuadi, Guanying Zhang, et al.
Pageof 4